Genmab — Januar 2021

[transalp]

Synes vi nærmer os gamle ath.. spændende:)

[Klarussen]

Så kører toget venner. Har du stadig dine bulls Pensionisten?

[E_L]

TEPEZZA full-year 2020 net sales exceeded $800 million, with double-digit sequential growth in the fourth quarter of 2020.

[E_L]

Horizon Therapeutics plc Provides Preliminary 2020 Financial Results https://www.businesswire.com/news/home/20210111005295/en/Horizon-Therapeutics-plc-Provides-Preliminary-2020-Financial-Results-Exceeding-Full-Year-2020-Net-Sales-and-Adjusted-EBITDA-Guidance-Provides-Update-on-TEPEZZA-teprotumumab-trbw-Supply-and-New-KRYSTEXXA-pegloticase-injection-Trials#.X_xCc5v9fgw.twitter

[Solsen]

De nærmer sig at Tapezza igen kan produceres. Men ellers rigtigt gode tal.

[E_L]

small new The DART Study- Daratumumab Treatment in ITP https://clinicaltrials.gov/ct2/show/NCT04703621

[Klarussen]

Ja ja, vi snuste da til ATH 2579

[Helge_LarsenPI-redaktør]

Genmab
@Genmab
·
2 t
Don’t miss us at #JPM21 on Jan 13 at 10 AM ET/ 4 PM CET! We’ll be discussing highlights of our #oncology research, innovative pipeline and priorities for 2021. https://jpmorgan.metameetings.net/events/healthc

[royal]

Link virker ikke.

[Helge_LarsenPI-redaktør]

Det her er vist bedre: https://jpmorgan.metameetings.net/events/healthcare21/general_signin

[royal]

Tak

[royal]

Fik dog ikke noget ud af det.....

[royal]

The agenda is made available only to confirm
ed attendees.

[royal]

Healthcare Conference

(www.jpmorgan.com)

[Sukkeralf]

Stadig gang i checkpoint deals

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Tirsdagens danske avisuddrag med DI, Vaccinepas og Coloplasthttps://www.proinvestor.com/investornyt/671005/tirsdagens-danske-avisuddrag-med-di-vaccinepas-og-coloplast

[E_L]

Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) https://seekingalpha.com/article/4398411-johnson-johnson-jnj-ceo-alex-gorsky-presents-39th-annual-jpmorgan-virtual-healthcare

[Sukkeralf]

Next is about the pipeline that we have. More than 10 compounds that we expect to file or launch over the next several years, all of which have more than a $1 billion worth of potential. These are really exciting areas certainly in areas such as oncology. For example the CD3s, both the CD3 and BCMA CD3 that we have and things like multiple myeloma. If you look at what we have in immunology, of course, the recent addition of Momenta, we're very excited about that as well.